title: Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major.
abstract: BACKGROUND
  Whereas certain oral antifungal azoles are well documented to have activity against leishmania, data on the efficacy of fluconazole for leishmaniasis are limited. We conducted a controlled trial in Saudi Arabia of fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major.
  
  
  METHODS
  This randomized, double-blind, placebo-controlled trial assessed the efficacy of oral fluconazole, in a dose of 200 mg daily for six weeks, in the treatment of parasitologically confirmed cutaneous leishmaniasis. The primary outcome measure was the time to the complete healing of all lesions.
  
  
  RESULTS
  A total of 106 patients were assigned to receive fluconazole, and 103 patients were assigned to receive placebo. Follow-up data were available for 80 and 65 patients, respectively. At the three-month follow-up, healing of lesions was complete for 63 of the 80 patients in the fluconazole group (79 percent) and 22 of the 65 patients in the placebo group (34 percent; relative risk of complete healing, 2.33 [95 percent confidence interval, 1.63 to 3.33]). According to an intention-to-treat analysis, the rates of healing were 59 percent and 22 percent, respectively (relative risk, 2.76 [95 percent confidence interval, 1.84 to 4.12]). Sodium stibogluconate was offered to 11 patients in the fluconazole group who returned for follow-up (14 percent) and 33 of those in the placebo group (51 percent) in whom oral treatment was judged to have failed. According to a Kaplan-Meier analysis, the time to healing was shorter for the fluconazole group (median, 8.5 weeks, as compared with 11.2 weeks in the placebo group; P<0.001 by the log-rank test). Side effects were mild and similar in both groups.
  
  
  CONCLUSIONS
  A six-week course of oral fluconazole is a safe and useful treatment for cutaneous leishmaniasis caused by L. major.
authors.affiliation: Department of Immunology and Infectious Diseases, Harvard School of Public Health, Brigham and Women's Hospital, Boston, MA, USA.
authors.forename: Abdulrahman A
authors.initials: AA
authors.lastname: Alrajhi
authors.forename: Elfaki A
authors.initials: EA
authors.lastname: Ibrahim
authors.forename: Edward B
authors.initials: EB
authors.lastname: De Vol
authors.forename: Mohammad
authors.initials: M
authors.lastname: Khairat
authors.forename: Rajab M
authors.initials: RM
authors.lastname: Faris
authors.forename: James H
authors.initials: JH
authors.lastname: Maguire
mesh_terms: D000328:Adult; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D019353:Endemic Diseases; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D018320:Leishmania major; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000453:epidemiology / Q000469:parasitology; D008297:Male; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D012529:Saudi Arabia / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole